Cited by 1,730Renal cell carcinoma treatmentEar and Head TumorsCancer, Hypoxia, and Metabolism

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Mutations of the VHL tumour suppressor gene in renal carcinoma

Gnarra, J.R., Tory, K., Weng, Y., Schmidt, L., Wei, M.H., Li, H., Latif, F., Liu, S., Chen, F., Duh, F.-M., Lubensky, I., Duan, D.R., Florence, C., Pozzatti, R., Walther, M. M., Bander, N.H., Grossman, H.B., Brauch, H., Pomer, S., Brooks, J.D., Isaacs, W.B., Lerman, M.I., Zbar, B., Linehan, W.M.·1994·Nature Genetics

DOI 10.1038/ng0594-85

Open this paper in CoChat — free account

Abstract

Multiple, bilateral renal carcinomas are a frequent occurrence in von Hippel-Lindau (VHL) disease. To elucidate the aetiological role of the VHL gene in human kidney tumorigenesis, localized and advanced tumours from 110 patients with sporadic renal carcinoma were analysed for VHL mutations and loss of heterozygosity (LOH). VHL mutations were identified in 57% of clear cell renal carcinomas analysed and LOH was observed in 98% of those samples. Moreover, VHL was mutated and lost in a renal tumour from a patient with familial renal carcinoma carrying the constitutional translocation, t(3;8)(p14;q24). The identification of VHL mutations in a majority of localized and advanced sporadic renal carcinomas and in a second form of hereditary renal carcinoma indicates that the VHL gene plays a critical part in the origin of this malignancy.

Integrity signals

Registry

Crossref · 10.1038/ng0594-85

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Identification of the von Hippel-Lindau Disease Tumor Suppressor Gene
Latif, F., Tory, K., Gnarra, J. R., Yao, M., Duh, F.-M. C., Orcutt, M. L., Stackhouse, T. M., Kuzmin, I., Modi, W. S., Geil, L., et al. (1993) · Science · doi:10.1126/science.8493574 · Cited by 2,971
Self-citation
The Results of Radical Nephrectomy for Renal Cell Carcinoma
Robson, C. J., Churchill, B. M., & Anderson, W. D. (1969) · The Journal of Urology · doi:10.1016/s0022-5347(17)62331-0 · Cited by 1,303
Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC
Donis-Keller, H., Dou, S., Chi, D., Carlson, K. M., Toshima, K., Lairmore, T. C., Howe, J. R., Moley, J. F., Goodfellow, P. J., & Wells, S. A. (1993) · Human Molecular Genetics · doi:10.1093/hmg/2.7.851 · Cited by 1,298
Hereditary cancer, oncogenes, and antioncogenes.
Knudson, A. G. (1985) · PubMed · Cited by 1,218
The Results of Radical Nephrectomy for Renal Cell Carcinoma
Robson, C. J., Churchill, B. M., & Anderson, W. D. (2016) · The Journal of Urology · doi:10.1016/j.juro.2016.10.095 · Cited by 1,160
A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma
Hofstra, R. M. W., Landsvater, R. M., Ceccherini, I., Stulp, R. P., Stelwagen, T., Luo, Y., Pasini, B., Höppener, J. W. M., van Amstel, H. K. P., Romeo, G., et al. (1994) · Nature · doi:10.1038/367375a0 · Cited by 1,143
Diseases of the kidney
Strauss, M. B., & Welt, L. G. (1963) · Little, Brown eBooks · Cited by 823
Mutations of the RET proto-oncogene in Hirschsprung's disease
Edery, P., Lyonnet, S., Mulligan, L. M., Pelet, A., Dow, E., Abel, L., Holder, S., Nihoul‐Feketé, C., Ponder, B. A. J., & Münnich, A. (1994) · Nature · doi:10.1038/367378a0 · Cited by 746
Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirschsprung's disease
Romeo, G., Ronchetto, P., Luo, Y., Barone, V., Seri, M., Ceccherini, I., Pasini, B., Bocciardi, R., Lerone, M., Kääriäinen, H., et al. (1994) · Nature · doi:10.1038/367377a0 · Cited by 698
Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC
Mulligan, L. M., Eng, C., Healey, C. S., Clayton, D. G., Kwok, J. B., Gardner, E., Ponder, M. A., Frilling, A., Jackson, C. E., Lehnert, H., et al. (1994) · Nature Genetics · doi:10.1038/ng0194-70 · Cited by 643

Show all 29 references

Research works printed but not linked: 1

Glenn, G.M., Choyke, P.L., Zbar, B. & Linehan, W.M. von Hippel-Lindau disease: clinical review and molecular genetics. Problems Urol. 4, 312–330 (1990).

Sorted by citations

Items 501–600 of 1,002

Renal Cell Carcinoma and Paraneoplastic IgA Nephropathy
Magyarlaki, T., Kiss, B., Buzogány, I., Fazekas, A., Sükösd, F., & Nagy, J. (1999) · The Nephron journals/Nephron journals · doi:10.1159/000045388 · Cited by 60
Precancerous Lesions in the Kidney
van Poppel, H., Nilsson, S. F., Ferran Algaba, B., Bergerheim, U. S. R., Cin, P. D., Fleming, S., Hellsten, S., Kırkalı, Z., Klotz, L. H., Lindblad, P., et al. (2000) · Scandinavian Journal of Urology and Nephrology · doi:10.1080/00365590050509887 · Cited by 60
Ca 2 + ‐activated K + channels in human melanoma cells are up‐regulated by hypoxia involving hypoxia‐inducible factor‐1α and the von Hippel‐Lindau protein
Tajima, N., Schönherr, K., Niedling, S., Kaatz, M., Kanno, H., Schönherr, R., & Heinemann, S. H. (2006) · The Journal of Physiology · doi:10.1113/jphysiol.2005.096818 · Cited by 63
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors
Polyzos, A. (2007) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2007.09.004 · Cited by 59
Sorafenib attenuates p21 in kidney cancer cells and augments cell death in combination with DNA-damaging chemotherapy
Inoue, H., Hwang, S. H., Wecksler, A. T., Hammock, B. D., & Weiss, R. H. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.12.9.17680 · Cited by 59
Hypoxic regulation of the noncoding genome and NEAT1
Choudhry, H., & Mole, D. R. (2015) · Briefings in Functional Genomics · doi:10.1093/bfgp/elv050 · Cited by 59
Comparative Sequence Analysis of the VHL Tumor Suppressor Gene
Woodward, E. R., Buchberger, A., Clifford, S. C., Hurst, L. D., Affara, N. A., & Maher, E. R. (2000) · Genomics · doi:10.1006/geno.2000.6144 · Cited by 59
Molecular Biology of Renal Cell Cancer and the Identification of Therapeutic Targets
Iliopoulos, O. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.8948 · Cited by 59
Major role for a 3p21 region and lack of involvement of the t(3;8) breakpoint region in the development of renal cell carcinoma suggested by loss of heterozygosity analysis
van den Berg, A., Hulsbeek, M. M. F., de Jong, D., Kok, K., Veldhuis, P. M. J. F., Roche, J., & Buys, C. H. C. M. (1996) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199601)15:1 · Cited by 59
Fhit in Human Cancer
Sozzi, G., Huebner, K., & Croce, C. M. (1998) · Advances in cancer research · doi:10.1016/s0065-230x(08)60766-6 · Cited by 59
Basic Research in Kidney Cancer
Oosterwijk, E., Rathmell, W. K., Junker, K., Brannon, A. R., Pouliot, F., Finley, D. S., Mulders, P., Kırkalı, Z., Uemura, H., & Belldegrun, A. S. (2011) · European Urology · doi:10.1016/j.eururo.2011.06.048 · Cited by 58
Hypoxic TAM-derived exosomal miR-155-5p promotes RCC progression through HuR-dependent IGF1R/AKT/PI3K pathway
Gu, W., Gong, L., Wu, X., & Yao, X. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00525-w · Cited by 58
A portrayal of E3 ubiquitin ligases and deubiquitylases in cancer
Satija, Y. K., Bhardwaj, A., & Das, S. (2013) · International Journal of Cancer · doi:10.1002/ijc.28129 · Cited by 58
The HIF-2α-Driven Pseudo-Hypoxic Phenotype in Tumor Aggressiveness, Differentiation, and Vascularization
Pietras, A., Johnsson, A. S., & Påhlman, S. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2010_72 · Cited by 62
Clinical implications of hypoxia inducible factor in renal cell carcinoma
Smaldone, M. C., & Maranchie, J. K. (2009) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2007.12.001 · Cited by 59
Mutation analysis of hypoxia-inducible factors HIF1A and HIF2A in renal cell carcinoma.
Morris, M. R., Hughes, D. J., Tian, Y.-M., Ricketts, C. J., Lau, K. W., Gentle, D., Shuib, S., Serrano‐Fernández, P., Lubiński, J., Wiesener, M. S., et al. (2009) · PubMed · Cited by 58
Self-citation
Cryptic von Hippel-Lindau disease: germline mutations in patients with haemangioblastoma only
Hes, F. J., McKee, S., TAPHOORN, M. J. B., Rehal, P., van der Luijt, R. B., McMahon, R., van der Smagt, J. J., Dow, D., Zewald, R. A., Whittaker, J., et al. (2000) · Journal of Medical Genetics · doi:10.1136/jmg.37.12.939 · Cited by 58
Role of chromosome 3p12-p21 tumour suppressor genes in clear cell renal cell carcinoma: analysis of VHL dependent and VHL independent pathways of tumorigenesis
Martinez, A. (2000) · Molecular Pathology · doi:10.1136/mp.53.3.137 · Cited by 58
Targeted therapies of cancer: Angiogenesis inhibition seems not enough
Roodink, I., & Leenders, W. P. J. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.09.004 · Cited by 57
An Important von Hippel-Lindau Tumor Suppressor Domain Mediates Sp1-Binding and Self-Association
Cohen, H. T., Zhou, M., Welsh, A. M., Zarghamee, S., Scholz, H., Mukhopadhyay, D., Kishida, T., Zbar, B., Knebelmann, B., & Sukhatme, V. P. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1767 · Cited by 57
Self-citation
The von Hippel–Lindau tumor suppressor protein influences microtubule dynamics at the cell periphery
Lolkema, M. P., Mehra, N., Jorna, A. S., van Beest, M., Giles, R. H., & Voest, E. E. (2004) · Experimental Cell Research · doi:10.1016/j.yexcr.2004.07.016 · Cited by 59
Hypoxia signaling: Challenges and opportunities for cancer therapy
Ivan, M., Fishel, M. L., Tudoran, O. M., Pollok, K. E., Wu, X., & Smith, P. J. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.10.002 · Cited by 57
Promoter Hypermethylation Profile of Kidney Cancer with New Proapoptotic p53 Target Genes and Clinical Implications
Christoph, F., Weikert, S., Kempkensteffen, C., Krause, H., Schostak, M., Köllermann, J. W., Miller, K., & Schrader, M. G. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0144 · Cited by 56
A novel role of sphingosine kinase‐1 in the invasion and angiogenesis of VHL mutant clear cell renal cell carcinoma
Salama, M., Carroll, B. L., Adada, M. M., Pulkoski‐Gross, M. J., Hannun, Y. A., & Obeid, L. M. (2015) · The FASEB Journal · doi:10.1096/fj.15-270413 · Cited by 59
The clinical implications of the genetics of renal cell carcinoma
Rosner, I. L., Bratslavsky, G., Pinto, P. A., & Linehan, W. M. (2009) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2008.11.001 · Cited by 56
Self-citation
Description of 2 angiogenic phenotypes in clear cell renal cell carcinoma
Edeline, J., Mottier, S., Vigneau, C. M., Jouan, F., Perrin, C., Zerrouki, S., Fergelot, P., Patard, J., & Rioux-Leclercq, N. C. (2012) · Human Pathology · doi:10.1016/j.humpath.2012.01.023 · Cited by 56
Validation of housekeeping gene and impact on normalized gene expression in clear cell Renal Cell Carcinoma: critical reassessment of YBX3/ZONAB/CSDA expression
Dupasquier, S., Delmarcelle, A.-S., Marbaix, É., Cosyns, J., Courtoy, P. J., & Pierreux, C. E. (2014) · BMC Molecular Biology · doi:10.1186/1471-2199-15-9 · Cited by 56
High expression levels of insulin-like growth factor–I receptor predict poor survival among women with clear-cell renal cell carcinomas
Parker, A. S., Cheville, J. C., Janney, C. A., & Cerhan, J. R. (2002) · Human Pathology · doi:10.1053/hupa.2002.126186 · Cited by 56
Identification of novel VHL target genes and relationship to hypoxic response pathways
Maina, E. N., Morris, M. R., Zatyka, M., Raval, R. R., Banks, R. E., Richards, F. M., Johnson, C. M., & Maher, E. R. (2005) · Oncogene · doi:10.1038/sj.onc.1208649 · Cited by 57
Inherited Carcinomas of the Kidney
Zbar, B., & Lerman, M. I. (1998) · Advances in cancer research · doi:10.1016/s0065-230x(08)60742-3 · Cited by 56
Self-citation
The role of histone H3K36me3 writers, readers and erasers in maintaining genome stability
Sharda, A., & Humphrey, T. C. (2022) · DNA repair · doi:10.1016/j.dnarep.2022.103407 · Cited by 63
Targeting the Hepatocyte Growth Factor/c-Met Signaling Pathway in Renal Cell Carcinoma
Harshman, L. C., & Choueiri, T. K. (2013) · The Cancer Journal · doi:10.1097/ppo.0b013e31829e3c9a · Cited by 55
Mutation analysis of HIF prolyl hydroxylases (PHD/EGLN) in individuals with features of phaeochromocytoma and renal cell carcinoma susceptibility
Astuti, D., Ricketts, C. J., Chowdhury, R., McDonough, M. A., Gentle, D., Kirby, G. A., Schlisio, S., Kenchappa, R. S., Carter, B. D., Kaelin, W. G., et al. (2010) · Endocrine Related Cancer · doi:10.1677/erc-10-0113 · Cited by 56
Self-citation
Von Hippel–Lindau Disease
McMahon, K., Findeis, S. K., & Findeis-Hosey, J. J. (2016) · Journal of Pediatric Genetics · doi:10.1055/s-0036-1579757 · Cited by 55
Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma
Tannir, N. M., Schwab, G. M., & Grünwald, V. (2017) · Current Oncology Reports · doi:10.1007/s11912-017-0566-9 · Cited by 55
Comprehensive Outline of Whole Exome Sequencing Data Analysis Tools Available in Clinical Oncology
Bartha, Á., & Győrffy, B. (2019) · Cancers · doi:10.3390/cancers11111725 · Cited by 58
The experimental renal cell carcinoma model in the chick embryo
Fergelot, P., Bernhard, J., Soulet, F., Kilarski, W. W., Léon, C., Courtois, N., Deminière, C., Herbert, J. M. J., Antczak, P., Francesco Falciani, B., et al. (2012) · Angiogenesis · doi:10.1007/s10456-012-9311-z · Cited by 55
Chromosome 3p allele loss in early invasive breast cancer: detailed mapping and association with clinicopathological features
Martínez, A., Walker, R. A., Shaw, J. A., Dearing, S. J., Maher, E. R., & Latif, F. (2001) · Molecular Pathology · doi:10.1136/mp.54.5.300 · Cited by 55
Self-citation
Chemotherapy in metastatic renal cell cancer
Lilleby, W. A., & Fosså, S. D. (2005) · World Journal of Urology · doi:10.1007/s00345-004-0469-x · Cited by 55
Role of Exon 2-encoded β-Domain of the von Hippel-Lindau Tumor Suppressor Protein
Bonicalzi, M.-E., Groulx, I., de Paulsen, N., & Lee, S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008295200 · Cited by 55
Phase II study of lenalidomide in patients with metastatic renal cell carcinoma
Choueiri, T. K., Dreicer, R., Rini, B. I., Elson, P., Garcia, J. A., Thakkar, S. G., Baz, R. C., Mekhail, T. M., Jinks, H. A., & Bukowski, R. M. (2006) · Cancer · doi:10.1002/cncr.22290 · Cited by 54
Targeted therapies and the treatment of non-clear cell renal cell carcinoma
Joaquim Bellmunt, B., & Dutcher, J. P. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt152 · Cited by 54
VHL mutations in renal cell cancer: does occupational exposure to trichloroethylene make a difference?
Brauch, H. B., Weirich, G., Klein, B., Rabstein, S., Bolt, H. M., & Brüning, T. (2004) · Toxicology Letters · doi:10.1016/j.toxlet.2003.12.074 · Cited by 54
Self-citation
Mineralocorticoid insufficiency due to suramin therapy
Kobayashi, K., Weiss, R. E., Vogelzang, N. J., Vokes, E. E., Janisch, L. A., & Ratain, M. J. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19961201)78:11 · Cited by 28
Cytogenetic and molecular characterization of random chromosomal rearrangements activating the drug resistance gene,MDR1/P-glycoprotein, in drug-selected cell lines and patients with drug refractory ALL
Knutsen, T., Mickley, L. A., Ried, T., Green, E. D., du Manoir, S., Schröck, E., Macville, M. V. E., Ning, Y., Robey, R. W., Polymeropoulos, M. H., et al. (1998) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199809)23:1 · Cited by 75
Somatic von hippel-lindau mutation in clear cell papillary cystadenoma of the epididymis
Gilcrease, M. Z., Schmidt, L. S., Zbar, B., Truong, L. D., Rutledge, M., & Wheeler, T. M. (1995) · Human Pathology · doi:10.1016/0046-8177(95)90299-6 · Cited by 54
Self-citation
Molecular Profiling and Classification of Sporadic Renal Cell Carcinoma by Quantitative Methylation Analysis
Gonzalgo, M. L., Yegnasubramanian, S., Yan, G., ROGERS, C. G., Nicol, T. L., Nelson, W. G., & Pavlovich, C. P. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0692 · Cited by 54
Segmental duplications and evolutionary plasticity at tumor chromosome break-prone regionsPreprint
Darai‐Ramqvist, E., Sandlund, A., Müller, S., Klein, G., Imreh, S., & Kost‐Alimova, M. (2008) · Genome Research · doi:10.1101/gr.7010208 · Cited by 54
Adjuvant therapy in renal cell carcinoma: Current knowledges and future perspectives
Larroquette, M., Peyraud, F., Domblides, C., Lefort, F., Bernhard, J., Ravaud, A., & Gross‐Goupil, M. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102207 · Cited by 54
Ubiquitin/SUMO Modification Regulates VHL Protein Stability and Nucleocytoplasmic Localization
Cai, Q., & Robertson, E. S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012636 · Cited by 53
Retracted
The role of angiogenesis in prostate and other urologic cancers: a review.
Izawa, J. I., & Dinney, C. P. (2001) · Europe PMC (PubMed Central) · Cited by 53
Renal cell carcinomas in trichloroethene(TRI) exposed persons are associated with somatic mutations in the von Hippel-Lindau ( VHL ) tumour suppressor gene
Brüning, T., Weirich, G., Hornauer, M. A., Höfler, H., & Brauch, H. B. (1997) · Archives of Toxicology · doi:10.1007/s002040050394 · Cited by 53
Self-citation
Antitumor protein therapy; Application of the protein transduction domain to the development of a protein drug for cancer treatment
Harada, H., Kizaka‐Kondoh, S., & Hiraoka, M. (2006) · Breast Cancer · doi:10.2325/jbcs.13.16 · Cited by 53
Renal cell carcinoma of end-stage renal disease
Hughson, M. D., Schmidt, L. S., Zbar, B., Daugherty, S., Meloni, A. M., Silva, F. G., & Sandberg, A. A. (1996) · Journal of the American Society of Nephrology · doi:10.1681/asn.v7112461 · Cited by 53
Self-citation
Identification and characterization of Birt–Hogg–Dubé associated renal carcinoma
Murakami, T., Sano, F., Huang, Y. K., Komiya, A., Baba, M., Osada, Y., Nagashima, Y., Kondo, K., Nakaigawa, N., Miura, T., et al. (2007) · The Journal of Pathology · doi:10.1002/path.2139 · Cited by 52
Management of von Hippel–Lindau-associated kidney cancer
Grubb, R. L., Choyke, P. L., Pinto, P. A., Linehan, W. M., & Walther, M. M. (2005) · Nature Clinical Practice Urology · doi:10.1038/ncpuro0179 · Cited by 52
Self-citation
Reduced Expression of Fumarate Hydratase in Clear Cell Renal Cancer Mediates HIF-2α Accumulation and Promotes Migration and Invasion
Sudarshan, S., Shanmugasundaram, K., Naylor, S. L., Lin, S., Livi, C. B., O’Neill, C. F., Parekh, D. J., Yeh, I., Sun, L., & Block, K. L. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021037 · Cited by 54
Overcome tumor heterogeneity-imposed therapeutic barriers through convergent genomic biomarker discovery: A braided cancer river model of kidney cancer
Hsieh, J. J.-D., Manley, B. J., Khan, N. A., Gao, J., Carlo, M. I., & Cheng, E. H. Y. (2016) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2016.09.002 · Cited by 54
Reliable gene mutation prediction in clear cell renal cell carcinoma through multi-classifier multi-objective radiogenomics model
Chen, X., Zhou, Z., Hannan, R., Thomas, K. M., Pedrosa, I., Kapur, P., Brugarolas, J., Mou, X., & Wang, J. (2018) · Physics in Medicine and Biology · doi:10.1088/1361-6560/aae5cd · Cited by 54
Identification of Somatic Chromosomal Abnormalities in Hypothalamic Hamartoma Tissue at the GLI3 Locus
Craig, D. W., Itty, A., Panganiban, C. B., Szelinger, S., Kruer, M. C., Sekar, A., Reiman, D., Narayanan, V., Stephan, D. A., & Kerrigan, J. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2007.10.006 · Cited by 52
Glucose transporter‐1 expression in renal cell carcinoma and its correlation with hypoxia inducible factor‐1α
Lidgren, A., Bergh, A. R. J., Grankvist, K., Rasmuson, T., & Ljungberg, B. (2007) · British Journal of Urology · doi:10.1111/j.1464-410x.2007.07238.x · Cited by 52
Von Hippel-Lindau disease
Maher, E. R. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)00391-h · Cited by 52
VHL gene alterations in renal cell carcinoma patients: novel hotspot or founder mutations and linkage disequilibrium
Ma, X., Yang, K., Lindblad, P., Egevad, L., & Hemminki, K. (2001) · Oncogene · doi:10.1038/sj.onc.1204692 · Cited by 52
Spoke‐wheel‐like enhancement as an important imaging finding of chromophobe cell renal carcinoma: A retrospective analysis on computed tomography and magnetic resonance imaging studies
Kondo, T., Nakazawa, H., Sakai, F., Kuwata, T., Onitsuka, S., Hashimoto, Y., & Toma, H. (2004) · International Journal of Urology · doi:10.1111/j.1442-2042.2004.00907.x · Cited by 52
Expression of Insulin-like Growth Factor I Receptor and Survival in Patients with Clear Cell Renal Cell Carcinoma
Parker, A. S., Cheville, J. C., Lohse, C. M., Cerhan, J. R., & Blute, M. L. (2003) · The Journal of Urology · doi:10.1097/01.ju.0000071474.70103.92 · Cited by 52
Susceptibility to vascular neoplasms but no increased susceptibility to renal carcinogenesis in Vhl knockout mice
Kleymenova, E. (2003) · Carcinogenesis · doi:10.1093/carcin/bgh017 · Cited by 52
Familial clear cell renal cell carcinoma (FCRC): clinical features and mutation analysis of the VHL,MET, and CUL2candidate genes
Woodward, E. R., Clifford, S. C., Astuti, D., Affara, N. A., & Maher, E. R. (2000) · Journal of Medical Genetics · doi:10.1136/jmg.37.5.348 · Cited by 52
Genetic susceptibility to cancer: ICRP Publication 79
Approved by the Commission in May 1997 (1998) · Annals of the ICRP · doi:10.1016/s0146-6435(98)00007-3 · Cited by 54
Serum endostatin levels are elevated in patients with soft tissue sarcoma
Feldman, A. L., Pak, H., Yang, J. C., Alexander, H. R., & Libutti, S. K. (2001) · Cancer · doi:10.1002/1097-0142(20010415)91:8 · Cited by 92
Detailed genetic and physical mapping of tumor suppressor loci on chromosome 3p in ovarian cancer.
Fullwood, P., Marchini, S., Rader, J. S., Martinez, A., Macartney-Coxson, D. P., Broggini, M., Morelli, M. C., Barbanti‐Brodano, G., Maher, E. R., & Latif, F. (1999) · PubMed · Cited by 52
Self-citation
Uncoupling hypoxia signaling from oxygen sensing in the liver results in hypoketotic hypoglycemic death
Kucejová, B., Sunny, N. E., Nguyen, A. D., Hallac, R. R., Fu, X., Peña‐Llopis, S., Mason, R. P., DeBerardinis, R. J., Xie, X.-J., DeBose‐Boyd, R. A., et al. (2011) · Oncogene · doi:10.1038/onc.2010.587 · Cited by 51
Clear cell carcinomas of the ovary and kidney: clarity through genomics
Ji, J. X. Y., Wang, Y. K., Cochrane, D. R., & Huntsman, D. D. (2018) · The Journal of Pathology · doi:10.1002/path.5037 · Cited by 52
On the Shoulders of Giants: The Evolution of Renal Cell Carcinoma Treatment—Cytokines, Targeted Therapy, and Immunotherapy
Dutcher, J. P., Flippot, R., Fallah, J., & Escudier, B. J. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280817 · Cited by 54
Hypercalcemia in Patients With Metastatic Renal Cell Carcinoma: Effect of Nephrectomy and Metabolic Evaluation
Walther, M. M., Patel, B. V., Choyke, P. L., Lubensky, I. A., Vocke, C. D., Harris, C. A., Venzon, D. J., Burtis, W. J., & Linehan, W. M. (1997) · The Journal of Urology · doi:10.1016/s0022-5347(01)64303-9 · Cited by 51
Self-citation
Cytologic analysis of papillary renal cell carcinoma
Granter, S. R., Pérez‐Atayde, A. R., & Renshaw, A. A. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19981025)84:5 · Cited by 51
Expression of the Von Hippel-Lindau Tumor Suppressor Gene, VHL, in Human Fetal Kidney and During Mouse Embryogenesis
Kessler, P., Vasavada, S. P., Rackley, R. R., Stackhouse, T. M., Duh, F.-M. C., Latif, F., Lerman, M. I., Zbar, B., & Williams, B. R. G. (1995) · Molecular Medicine · doi:10.1007/bf03401583 · Cited by 51
Self-citation
Detailed deletion mapping on chromosome arm 12q in human pancreatic adenocarcinoma: Identification of a 1-cM region of common allelic loss
Kimura, M., Abe, T., Sunamura, M., Matsuno, S., & Horii, A. (1996) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199610)17:2 · Cited by 75
Recent Developments in the Pathology of Renal Tumors: Morphology and Molecular Characteristics of Select Entities
Yan, B. C., Mackinnon, A. C., & Al‐Ahmadie, H. A. (2009) · Archives of Pathology & Laboratory Medicine · doi:10.5858/133.7.1026 · Cited by 50
Hypoxia drives glucose transporter 3 expression through hypoxia-inducible transcription factor (HIF)–mediated induction of the long noncoding RNA NICI
Lauer, V., Grampp, S., Platt, J. L., Lafleur, V. N., Lombardi, O., Choudhry, H., Kranz, F., Hartmann, A., Wullich, B., Yamamoto, A., et al. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.009827 · Cited by 50
Towards a new WHO classification of renal cell tumor: what the clinician needs to know—a narrative review
Cimadamore, A., Liang Cheng, C., Scarpelli, M., Massari, F., Mollica, V., Santoni, M., Antonio Lopez-beltran, B., Montironi, R., & Moch, H. (2021) · Translational Andrology and Urology · doi:10.21037/tau-20-1150 · Cited by 50
Genetic Basis of Cancer of the Kidney
Sudarshan, S., & Linehan, W. M. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.06.008 · Cited by 50
Self-citation
The In vitro and In vivo Effects of Re-Expressing Methylated von Hippel-Lindau Tumor Suppressor Gene in Clear Cell Renal Carcinoma with 5-Aza-2′-deoxycytidine
Alleman, W. G., Tabios, R., Chandramouli, G. V. R., Aprelikova, O. N., Torres-Cabala, C. A., Mendoza, A., Rodgers, C., Sopko, N. A., Linehan, W. M., & Vasselli, J. R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0516 · Cited by 50
Self-citation
Normal and Abnormal Development of the Kidney: A Clinician???s Interpretation of Current Knowledge
Glassberg, K. I. (2002) · The Journal of Urology · doi:10.1016/s0022-5347(05)64982-8 · Cited by 50
Germ‐line Mutation Analysis in Patients with von Hippel‐Lindau Disease in Japan: An Extended Study of 77 Families
Yoshida, M., Ashida, S., Kondo, K., Kobayashi, K., Kanno, H., Shinohara, N., Shitara, N., Kishida, T., Kawakami, S., Baba, M., et al. (2000) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.2000.tb00933.x · Cited by 50
Loss of heterozygosity at 3p14.2 in clear cell renal cell carcinoma is an early event and is highly localized to the FHIT gene locus.
Velickovic, M., Delahunt, B., & Grebe, S. K. (1999) · PubMed · Cited by 50
SLIT2 promoter methylation analysis in neuroblastoma, Wilms' tumour and renal cell carcinoma
Astuti, D., da Silva, N. F., Dallol, A., Gentle, D., Martinsson, T., Kogner, P., Grundy, R. G., Kishida, T., Yao, M., Latif, F., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601447 · Cited by 50
Self-citation
Targeting Tyrosine kinases in Renal Cell Carcinoma: “New Bullets against Old Guys”
Alonso‐Gordoa, T., García‐Bermejo, L., Grande, E., Garrido, P., Carrato, A., & Molina‐Cerrillo, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081901 · Cited by 50
LC3C-Mediated Autophagy Selectively Regulates the Met RTK and HGF-Stimulated Migration and Invasion
Bell, E. S., Coelho, P. P., Ratcliffe, C. D. H., Rajadurai, C. V., Peschard, P., Vaillancourt, R., Zuo, D., & Park, M. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.11.063 · Cited by 53
Genetic and epigenetic profile of sporadic pheochromocytomas
Cascón, A., Ruiz-Llorente, S., Fraga, M. F., Leton, R., Telleria, D., Sastre, J., Diez, J. J., Diaz-Guerra, G. M., Perez, J. A. D., Benitez, J., et al. (2004) · Journal of Medical Genetics · doi:10.1136/jmg.2003.012658 · Cited by 49
Investigation of the role of SDHB inactivation in sporadic phaeochromocytoma and neuroblastoma
Astuti, D., Morris, M. R., Krona, C. C., Abel, F., Gentle, D., Martinsson, T., Kogner, P., Neumann, H. P. H., Voutilainen, R., Eng, C., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602202 · Cited by 49
Self-citation
Sporadic human renal tumors display frequent allelic imbalances and novel mutations of the HRPT2 gene
Zhao, J., Yart, A., Frigerio, S., Perren, A. A., Schraml, P., Weisstanner, C., Stallmach, T., Krek, W., & Moch, H. (2006) · Oncogene · doi:10.1038/sj.onc.1210131 · Cited by 49
Molecular pathology of von Hippel–Lindau disease and the VHL tumour suppressor gene
Richards, F. M. (2001) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399401002654 · Cited by 49
Molecular pathogenesis of the von Hippel-Lindau hereditary cancer syndrome: implications for oxygen sensing.
Yang, H., & Kaelin, W. G. (2001) · PubMed · Cited by 49
Molecular differential diagnosis of renal carcinoma: from microscopes to microsatellites.
Steiner, G. E., & Sidransky, D. (1996) · Europe PMC (PubMed Central) · Cited by 49
Loss of heterozygosity on the short arm of chromosome 3 in sporadic, von hippel‐lindau disease‐associated, and familial pheochromocytoma
Zeiger, M. A., Zbar, B., Keiser, H. R., Linehan, W. M., & Gnarra, J. R. (1995) · Genes Chromosomes and Cancer · doi:10.1002/gcc.2870130303 · Cited by 49
Self-citation
Elongin C (ELOC/TCEB1)-associated von Hippel–Lindau disease
Andreou, A., Yngvadóttir, B., Bassaganyas, L., Clark, G. R., Martín, J., Whitworth, J., Cornish, A. J., Houlston, R. S., Rich, P. M., Egan, C. A., et al. (2022) · Human Molecular Genetics · doi:10.1093/hmg/ddac066 · Cited by 50
Lack of mutation of the folliculin gene in sporadic chromophobe renal cell carcinoma and renal oncocytoma
Nagy, A., Zoubakov, D., Stupar, Z., & Kovács, G. (2004) · International Journal of Cancer · doi:10.1002/ijc.11694 · Cited by 49
Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon‐α2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial
Sergio Bracarda, A., Joaquim Bellmunt, B., Melichar, B., Négrier, S., Bajetta, E., Ravaud, A., Šneller, V., & Escudier, B. J. (2010) · British Journal of Urology · doi:10.1111/j.1464-410x.2010.09707.x · Cited by 48
Genomics and clinical correlates of renal cell carcinoma
Mitchell, T. J., Rossi, S. H., Klatte, T., & Stewart, G. D. (2018) · World Journal of Urology · doi:10.1007/s00345-018-2429-x · Cited by 49
Clinical and molecular analysis of disseminated hemangioblastomatosis of the central nervous system in patients without von Hippel—Lindau disease
Weil, R. J., Vortmeyer, A. O., Zhuang, Z., Pack, S., Theodore, N., Erickson, R. K., & Oldfield, E. H. (2002) · Journal of neurosurgery · doi:10.3171/jns.2002.96.4.0775 · Cited by 48

Authors: Gnarra, J. R., Tory, K., Weng, Y., Schmidt, L., Wei, M. H., Li, H., Latif, F., Liu, S., Chen, F., Duh, F.-M., Lubensky, I., Duan, D. R., Florence, C., Pozzatti, R., Walther, M. M., Bander, N. H., Grossman, H. B., Brauch, H., Pomer, S., Brooks, J. D., Isaacs, W. B., Lerman, M. I., Zbar, B., & Linehan, W. M.
Affiliations: National Cancer Institute (US)
Frederick National Laboratory for Cancer Research (US)
National Institutes of Health (US)
Cornell University (US)
University of Michigan (US)
Technical University of Munich (DE)
Heidelberg University (DE)
Johns Hopkins University (US)
ORCID: Gnarra, J.R.
Schmidt, L.
Wei, M.H.
Lubensky, I.
Bander, N.H.
Brauch, H.
Brooks, J.D.
Isaacs, W.B.
Lerman, M.I.
Linehan, W.M.
Venue: Nature Genetics
Publisher: Springer Science and Business Media LLC
Published: 1994-05
Volume: 7
Issue: 1
Pages: 85-90
ISSN: 1061-4036 (ISSN-L)
1546-1718
DOI: 10.1038/ng0594-85
OpenAlex: W2010160635
Cited by: 1,730
References: 29
Citations by year: 2026: 17 · 2025: 25 · 2024: 30 · 2023: 38 · 2022: 38 · 2021: 45 · 2020: 56 · 2019: 47 · 2018: 45 · 2017: 42 · 2016: 57 · 2015: 35 · 2014: 70 · 2013: 66 · 2012: 62
FWCI: 61.77
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature Genetics (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
Health Sciences › Medicine › Oncology › Ear and Head Tumors
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
Keywords: VHL gene, von Hippel-Lindau disease, renal carcinoma, clear cell renal cell carcinoma, loss of heterozygosity
MeSH terms: Base Sequence, Carcinoma, DNA Mutational Analysis, DNA, Neoplasm, von Hippel-Lindau Disease, Humans, Kidney Neoplasms, Molecular Sequence Data, Mutation, Organ Specificity, Polymorphism, Restriction Fragment Length, Genes, Tumor Suppressor, Neoplasms, Second Primary, Sequence Deletion, Adenocarcinoma, Clear Cell

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Mutations of the VHL tumour suppressor gene in renal carcinoma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks